Northwestern Mutual Wealth Management Co. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 7,295 shares of the medical equipment provider’s stock, valued at approximately $628,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. DV Equities LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at about $25,000. Tacita Capital Inc bought a new position in Zimmer Biomet in the second quarter worth approximately $26,000. Monetary Solutions Ltd bought a new position in Zimmer Biomet in the fourth quarter worth approximately $30,000. Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $31,000. Finally, Elevation Wealth Partners LLC increased its holdings in shares of Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares in the last quarter. 88.89% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the company. Truist Financial increased their target price on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Royal Bank Of Canada upped their price objective on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Citigroup dropped their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Barclays decreased their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. Finally, Canaccord Genuity Group raised their price target on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $104.42.
Zimmer Biomet Trading Up 1.2%
Shares of ZBH stock opened at $101.41 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market capitalization of $19.34 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 2.72 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $107.85. The company has a 50-day simple moving average of $93.40 and a two-hundred day simple moving average of $91.31.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.
Insiders Place Their Bets
In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.28% of the company’s stock.
About Zimmer Biomet
Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.
Featured Stories
- Five stocks we like better than Zimmer Biomet
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
